Main Conference Day 3Friday, 29 May 2026 - European Time GMT+1

Ficerafusp alfa, is a first-in-class EGFR-TGF-b bifunctional antibody. TGF-β signaling within the tumor microenvironment (TME) creates fibrotic, immunosuppressive barriers that impede tumor penetration of immune cells. Mechanistic insights from paired biopsies and preclinical studies reveal the importance of tumor targeted inhibition of TGF- b in breaking down barriers to tumor penetration. Ultimately, ficerafusp alfa’s tumor penetration has the potential to drive deep and durable responses that lead to long-term clinical benefits.

TAVO412 is an avidity driven trispecific antibody that engages multiple mechanisms of action to control different resistance mechanisms in solid tumors. We describe confirmation of target engagement in Phase 1A trials for patients struggling with mutant lung, esophageal, and colorectal cancers. In addition, we highlight the pharmacokinetic profiles, tolerability, and clinical responses.

Gyes is a science-driven biotech focused on advancing antibody therapeutics through the rational engineering of multispecific formats. We have developed a Multispecific Antibody Platform that leverages avidity engineering to design next-generation antibodies with enhanced selectivity and controllable functionality. Our approach enables conditional activation through the combinatorial engagement of co-expressed targets on defined cell populations. This mechanism allows selective modulation of immune cell function, improving therapeutic precision while minimizing off-target activity.

Adeno-associated virus (AAV) gene therapies face challenges in tissue-specific delivery and safety. We have developed bispecific Altibody for precise AAV retargeting to muscle and CNS. This innovative "plug-and-play" approach enhances on-target transduction efficacy and safety in mice, marking a milestone in AAV retargeting strategies for gene therapy applications.